Group 1 - The core viewpoint of the articles indicates that the technology sector is expected to attract incremental capital, with 16 technology-themed funds approved on November 21, signaling strong investor interest in this area [1][5][8] - The approved funds include the first batch of science and technology entrepreneurship artificial intelligence ETFs from seven fund companies, reflecting a focus on companies involved in AI [2][4] - The issuance of these funds is anticipated to bring at least 30 billion yuan in new capital, as the majority of the funds are not initiated funds, with only one being an initiated fund [5][6] Group 2 - The recent trend shows a significant recovery in new fund issuances, with 73 equity funds established in November alone, averaging around 600 million yuan in issuance size [6][8] - There is a notable demand for technology-themed funds, with some experiencing oversubscription, such as the E Fund Technology Pioneer Mixed Fund, which had effective subscription applications exceeding its 2 billion yuan cap [6][8] - Institutional investors remain optimistic about the technology sector, despite recent market volatility, with continued inflows into AI-themed ETFs, indicating a belief in the long-term growth potential of the AI industry [9][10]

Core Viewpoint - The stock of Jia Bi You experienced a decline of 2.04% on November 21, with a current price of 23.04 CNY per share, reflecting a significant drop in recent trading days [1] Company Overview - Jia Bi You Biotechnology (Wuhan) Co., Ltd. was established on September 22, 2004, and went public on December 19, 2019. The company specializes in the research, production, and sales of polyunsaturated fatty acids such as ARA and DHA, as well as natural β-carotene, with applications in infant formula, dietary supplements, and special medical foods [2] - The revenue composition of Jia Bi You includes ARA products at 76.16%, DHA products at 21.24%, and other supplements at 2.60% [2] - The company is classified under the basic chemical industry, specifically in chemical products related to food and feed additives, and is associated with concepts such as pet economy, synthetic biology, cosmetics, multiple births, and Hubei Free Trade Zone [2] Financial Performance - For the period from January to September 2025, Jia Bi You achieved a revenue of 428 million CNY, representing a year-on-year growth of 10.56%. The net profit attributable to the parent company was 129 million CNY, showing a significant increase of 54.18% [2] - Since its A-share listing, Jia Bi You has distributed a total of 243 million CNY in dividends, with 103 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, the number of shareholders for Jia Bi You was 8,362, an increase of 1.01% from the previous period, while the average circulating shares per person decreased by 1.00% to 20,127 shares [2] - Notably, several institutional investors, including 华夏稳增混合 and 鹏华优质治理混合(LOF)A, have exited the list of the top ten circulating shareholders [3]

Core Viewpoint - The article highlights the importance of supporting rural children's growth and education, showcasing the "Youyi New Bud" Sunshine Care Program by Jiabiou Biotechnology, which aims to provide safety and support for students in rural areas [1][2]. Group 1: Company Initiatives - Jiabiou Biotechnology has launched the "Youyi New Bud" Sunshine Care Program, collaborating with various partners to provide tailored safety uniforms and winter pants to 189 students at a primary school in Laifeng County [1][2]. - The program follows a mature public welfare model of "material donation + knowledge transfer," emphasizing both material support and educational empowerment for rural children [1][2]. Group 2: Community Impact - The donated "Siyuan Ark" safety uniforms are designed with reflective strips to enhance visibility in low-light conditions, increasing the distance at which drivers can see students to over 150 meters [2]. - The initiative reflects a collaborative effort among local organizations, including the Laifeng County Golden Sun Public Welfare Association, to innovate public welfare models and support rural education [2][3]. Group 3: Future Directions - Laifeng County plans to continue fostering public welfare cooperation platforms to channel quality resources into rural education and child care [3]. - Jiabiou Biotechnology aims to deepen its commitment to public welfare while maintaining its focus on its core biotechnology business, demonstrating corporate social responsibility [3].

Core Insights - The article highlights the significant transformation in the industrial sector driven by biotechnology, emphasizing its role in achieving sustainable growth and meeting carbon neutrality goals [1][2][3] - The Chinese government has officially included biomanufacturing in its national strategy, indicating a strong commitment to advancing this sector through unprecedented measures and a national framework [1][10] - The biomanufacturing industry is projected to capture one-third of the global manufacturing output by the end of the century, creating a market worth approximately $30 trillion [4] Industry Overview - Biomanufacturing is transitioning traditional industries from high-energy, high-emission chemical processes to low-energy, low-pollution biological processes, which is essential for sustainable development [2][12] - The industry is gaining momentum globally due to its economic advantages, mild reaction conditions, and renewable raw materials, leading to a new industrial revolution [3] Government Initiatives - The Ministry of Industry and Information Technology (MIIT) has initiated the selection of "biomanufacturing landmark products" and "biomanufacturing pilot platforms," reflecting the strategic intent to identify and cultivate leading industry examples [5][10] - The MIIT's focus on key areas such as biomanufacturing, integrated circuits, and advanced materials aims to achieve decisive breakthroughs in core technologies [13] Company Spotlight: Jia Bi You - Jia Bi You has emerged as a focal point in the industry, successfully developing 2'-fucosyllactose (2'-FL), a human milk oligosaccharide with significant immune-regulating properties, which has been recognized as a landmark product by the MIIT [7][10] - The company has also been included in the first batch of biomanufacturing pilot capacity construction platforms and high-performance bioreactor innovation tasks, showcasing its advanced technology and market potential [8][9] Technological Advancements - Jia Bi You integrates artificial intelligence with synthetic biology to create an intelligent research and development platform, enhancing its capabilities in enzyme design and microbial strain development [18][37] - The company has developed a comprehensive biomanufacturing platform that includes advanced fermentation systems and real-time monitoring technologies, significantly improving production efficiency and product quality [18][21] Market Position and Growth - Jia Bi You has established itself as a leader in the biomanufacturing sector, with a diverse product portfolio that includes ARA, DHA, and various high-value nutrients, positioning itself to capture significant market opportunities [27][36] - The company has successfully penetrated international markets, collaborating with major global players and obtaining necessary certifications for its products, thereby expanding its global footprint [41][42] Future Prospects - The biomanufacturing sector is expected to experience rapid growth, driven by government support and technological innovation, with Jia Bi You poised to play a pivotal role in this transformation [45][46] - The establishment of innovation centers and collaborative initiatives in regions like Hubei is expected to enhance the overall competitiveness of the biomanufacturing industry in China [29][34]

Core Viewpoint - On November 18, 2025, the company announced the election of Mr. Yi Huarong as the employee director of the fourth board of directors during the first employee representative meeting of 2025 [1] Group 1 - The company held its first employee representative meeting of 2025 on November 18 [1] - Mr. Yi Huarong was elected as the employee director by a vote from all attending employee representatives [1]

证券代码：688089 证券简称：嘉必优 公告编号：2025-082 嘉必优生物技术（武汉）股份有限公司 （二）离任对公司的影响 根据《中华人民共和国公司法》《公司章程》及相关规定，公司已及时选举 了职工董事，张春雨女士辞职后不会导致公司董事会成员低于法定最低人数，不 会影响董事会依法规范运作，也不会影响公司正常的经营发展，张春雨女士的辞 职报告自送达公司董事会之日起生效。 截至本公告披露之日，张春雨女士不直接持有公司股份，不存在应当履行而 未履行的承诺事项。 二、补选职工董事的情况 根据《公司法》《上海证券交易所科创板股票上市规则》等法律法规以及《公 司章程》的相关规定，公司于 2025 年 11 月 18 日召开了 2025 年第一次职工代表 关于董事辞职暨选举职工董事的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事辞职情况 （一）提前离任的基本情况 嘉必优生物技术（武汉）股份有限公司（以下简称"公司"）董事会于近日收 到公司非独立董事张春雨女士递交的书面辞职报告。张春雨女士提前离任的基本 情况如下： ...

（二） 股东大会召开的地点：武汉市东湖新技术开发区高科园三路 89 号公司会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 62 | | --- | --- | | 普通股股东人数 | 62 | | 2、出席会议的股东所持有的表决权数量 | 83,415,142 | | 普通股股东所持有表决权数量 | 83,415,142 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 50.1114 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 50.1114 | 证券代码：688089 证券简称：嘉必优 公告编号：2025-081 嘉必优生物技术（武汉）股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 11 月 18 ...

北京市恒源（武汉）律师事务所 法律意见书 北京市恒源（武汉）律师事务所 关于嘉必优生物技术（武汉）股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：嘉必优生物技术（武汉）股份有限公司 根据《中华人民共和国证券法》（以下简称《证券法》）、《中华人民共和 国公司法》（以下简称《公司法》）和中国证券监督管理委员会《上市公司股东 会规则》（以下简称《股东会规则》）等法律、行政法规、规范性文件及《嘉必 优生物技术（武汉）股份有限公司章程》（以下简称《公司章程》）的要求，北 京市恒源（武汉）律师事务所（以下简称本所）接受嘉必优生物技术（武汉）股 份有限公司（以下简称公司）的委托，指派律师出席公司2025年第二次临时股东 大会（以下简称本次股东大会）。 本所声明：本所律师仅对本次股东大会的召集程序、召开程序、出席会议人 员资格、召集人资格、表决程序、表决结果发表法律意见，并不对本次股东大会 所审议的议案、议案所涉及的数字及内容发表意见。本所律师同意将本法律意见 书随本次股东大会其他信息披露资料一并公告。 本法律意见书仅供见证公司本次股东大会相关事项的合法性之目的使用，不 得用作任何其他目的。 本所及经办律师依 ...

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [5] Core Insights - The application of Human Milk Oligosaccharides (HMOs) is expected to accelerate, driven by their recognized nutritional benefits and expanding regulatory approvals [3] - The infant formula market is experiencing increased concentration, with the top 10 companies' market share rising from 68% in 2017 to 83% in Q3 2025, indicating a shift towards premium product offerings that include HMOs [2] - The potential market space for HMOs in the Chinese infant formula sector is estimated to be between 5.86 billion to 11.72 billion yuan, based on projected production and pricing [2] Summary by Sections HMO Nutritional Benefits - HMOs are the third largest nutritional component in breast milk, consisting of various structures that contribute positively to infant health, including growth, gut health, immunity, and cognitive development [1] Market Dynamics - The implementation of stringent new standards for infant formula has led to significant market consolidation and a focus on nutritional enhancement, with major brands introducing HMO-enriched products [2] - The expected production of infant formula in China for 2024 is approximately 1.563 million tons, with a significant portion anticipated to be high-end products requiring HMO addition [2] Regulatory Developments - Recent approvals by health authorities to expand the use of HMOs in various food products indicate a growing recognition of their value, which could lead to exponential market growth if HMOs are utilized beyond infant formula [3] - Companies like Ganbaiyou and Qiu Tian Man Man are already responding to these regulatory changes by launching HMO-added products [3] Company Focus - Companies such as Langkun Technology, Baolingbao, and Jiabiyou are actively developing HMO production capabilities, with significant annual production capacities planned [10]

嘉必优生物技术(武汉)股份有限公司 2025年第二次临时股东大会会议资料 嘉必优生物技术(武汉)股份有限公司 2025 年第二次临时股东大会 会议资料 2025 年 11 月 18 日 | 2025 年第二次临时股东大会会议须知 2 | | --- | | 2025 年第二次临时股东大会会议议程 4 | | 2025 年第二次临时股东大会会议议案 6 | | 议案一：关于取消监事会、变更注册地址并修订《公司章程》的议案 6 | | 议案二：关于修订部分公司治理制度的议案 8 | 嘉必优生物技术(武汉)股份有限公司 2025年第二次临时股东大会会议资料 嘉必优生物技术（武汉）股份有限公司 2025 年第二次临时股东大会会议须知 为维护广大投资者的合法权益，保障股东在本次股东大会期间依法行使权利， 根据《公司法》、中国证监会《上市公司股东大会规则》和嘉必优生物技术（武 汉）股份有限公司（以下简称"公司"）《股东大会议事规则》等有关规定，特制 定本会议须知： 一、公司负责本次股东大会的议程安排和会务工作，出席会议人员应当听从 公司工作人员安排，共同维护好会议秩序。 二、为保证股东大会的正常秩序，除出席会议的股东或者 ...